Paper11387
Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes.
Harms HH. Life Sci, 1976. Cited by 27 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes. Papers, record 11387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11387
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adipose Tissue | Major topic |
| Adrenergic beta-Antagonists | Major topic |
| Receptors, Adrenergic | Major topic |
| Receptors, Adrenergic, beta | Major topic |
| Animals | |
| Epididymis | |
| Fatty Acids, Nonesterified | |
| Humans | |
| Kinetics | |
| Male | |
| Rats | |
| Species Specificity | |
| Stereoisomerism | |
| Structure-Activity Relationship |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,136,585 | Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes? | Biomolecules | 2023 | https://conductscience.org/library/papers/38136585 | PubMed |
| 26,612,506 | Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs. | Naunyn Schmiedebergs Arch Pharmacol | 2016 | https://conductscience.org/library/papers/26612506 | PubMed |
| 18,612,674 | The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. | Naunyn Schmiedebergs Arch Pharmacol | 2008 | https://conductscience.org/library/papers/18612674 | PubMed |
| 6,125,168 | Beta-adrenoceptor blocking agents and lipolysis. | Br J Clin Pharmacol | 1982 | https://conductscience.org/library/papers/6125168 | PubMed |
| 2,983,800 | Atypical characteristics of the beta-adrenoceptor mediating cyclic AMP generation and lipolysis in the rat adipocyte. | Br J Pharmacol | 1985 | https://conductscience.org/library/papers/2983800 | PubMed |
| 23,133 | Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. | Br J Clin Pharmacol | 1978 | https://conductscience.org/library/papers/23133 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11387
GET https://conductscience.org/api/papers/v1/11387/authors